Clinical Trial Update: Edrecolomab in Treating Patients With Stage II Colon Cancer [Phase 3]

View source ↗

Summary

Edrecolomab was evaluated in a Phase 3 trial for stage II colon cancer, including mucinous and signet-ring histologies. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Mucinous Adenocarcinoma of the Colon
• Signet Ring Adenocarcinoma of the Colon

Drugs mentioned

• Edrecolomab (edrecolomab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Mucinous Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Colon | Phase 3 | Status: COMPLETED